Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Status:
Terminated
Trial end date:
2020-05-22
Target enrollment:
Participant gender:
Summary
This is an international, multicentre, parallel-group, randomised, double-blind, placebo
controlled, phase II study to evaluate the benefits and risks of using sodium zirconium
cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor
(RAASi) therapy in heart failure patients.